SGO on the GO – Détails, épisodes et analyse

Carolyn Haunschild , MD and Sameer Sharma, MD, from the SGO Coding and Reimbursement Subcommittee share their expertise in E/M coding and discuss how risk of complications, morbidity and mortality of patient management factor into billing of inpatient and outpatient visits.  One episode in a continuing series of podcasts on the basics of CPT coding from the SGO. Moderated by David Holtz, MD, Past Chair of the SGO Coding and Reimbursement Subcommittee.

Kimberly Levinson, MD, MPH, and Kaitlin Nicholson, MD, from the SGO Coding and Reimbursement Committee share their expertise in E/M coding to demystify the use of medical complexity data to support your billing of inpatient and outpatient visits.  One episode in a continuing series of podcasts on the basics of CPT coding from the SGO. Moderated by David Holtz, MD, Past Chair of the SGO Coding and Reimbursement Committee. 

This is the first of the three-part podcast series, Keeping up with the Chemos on CDK 4/6 inhibitors. After going over some general information on CDK 4/6 inhibitors including when to use the drug, toxicity, response rates, repeat biopsy, and line of therapy and treatment option. The multidisciplinary panel will discuss dosing and drug preparation for giving CDK 4/6 inhibitors. The session wraps up with some key take home points on CDK 4/6 inhibitors.

2024-2025 SGO Chemotherapy and Immunology Subcommittee Lead and Moderator:
Jennifer MacDonald, PharmD, BCOP
 
Speakers: 
Julia Fehniger, MD
Jodi L. Taraba, PharmD, MS, RPh, BCOP
Siddhartha Yadav, M.B.B.S, MD

Let’s do this -- This podcast features patient advocates who share their experiences and offer valuable insights from their journeys as cervical cancer patients and survivors. It is hosted by the Health Equity Subcommittee, a division of the SGO Diversity, Inclusion, and Health Equity (DIHE) Committee.

Moderators:

• Lindsay Kuroki, MD, MSCI, Washington University Physicians, DIHE Health Equity subcommittee Chair
• Nancy Zhou, MD, Rutgers Health - NJMS, DIHE Health Equity subcommittee Member

 Speakers:

• Mindy Dunn, Cancer Survivor
• Linda Ryan, Cancer Survivor and Patient Advocate 

Resource Links:
Foundation for Women's Cancer (FWC) Cervical Cancer: Your Guide 

This is the last of the three-part podcast series, Keeping up with the Chemos on Trastuzumab Deruxtecan ENHERTU®. Our multidisciplinary panel will discuss the challenges with patient monitoring while on Trastuzumab Deruxtecan ENHERTU®. When to dose adjust and hold or even discontinue Trastuzumab Deruxtecan ENHERTU®. Once again, the podcast ends with take home points for patient monitoring and side effects while on Trastuzumab Deruxtecan ENHERTU®.  

2023-2024 SGO Chemotherapy and Targeted Therapies Subcommittee Member and Moderator:
Tracilyn Hall, MD

Speakers:
Jennifer MacDonald, PharmD, BCOP
Kathleen Moore, MD
Bernard Tawfik, MD 

In honor of Endometrial Cancer Awareness Month, we encourage you to read the latest HER2 Molecular Card and Trastuzumab Deruxtecan ENHERTU® Chemotherapy Card available now on SGO ConnectEd.

HER2 Molecular Card: https://connected.sgo.org/content/molecular-target-human-epidermal-growth-factor-receptor-2-her2

Trastuzumab Deruxtecan ENHERTU® Chemotherapy Card: https://connected.sgo.org/content/chemotherapy-targeted-therapies-flash-cards

This is the second of the three-part podcast series, Keeping up with the Chemos on Trastuzumab Deruxtecan ENHERTU®.  Our multidisciplinary panel will discuss the important information about the drug preparation and administration of Trastuzumab Deruxtecan ENHERTU®.  Focusing on dosing, breast scoring, HER2, infusion reactions, lab examinations, and patient education. The session ends with general take home points on administration and toxicity prevention interventions.

2023-2024 SGO Chemotherapy and Targeted Therapies Subcommittee Member and Moderator:
Tracilyn Hall, MD

Speakers:
Jennifer MacDonald, PharmD, BCOP
Kathleen Moore, MD
Bernard Tawfik, MD 

In honor of Endometrial Cancer Awareness Month, we encourage you to read the latest HER2 Molecular Card and Trastuzumab Deruxtecan ENHERTU® Chemotherapy Card available now on SGO ConnectEd.

HER2 Molecular Card: https://connected.sgo.org/content/molecular-target-human-epidermal-growth-factor-receptor-2-her2

Trastuzumab Deruxtecan ENHERTU® Chemotherapy Card: https://connected.sgo.org/content/chemotherapy-targeted-therapies-flash-cards

This is the first of the three-part podcast series, Keeping up with the Chemos on Trastuzumab Deruxtecan ENHERTU®. After going over some general information on Trastuzumab Deruxtecan ENHERTU® including when to use the drug, checking patient performance status, toxicity, response rates in breast, and line of therapy and treatment option. The multidisciplinary panel will discuss dosing and drug preparation for giving Trastuzumab Deruxtecan ENHERTU®. The session wraps up with some key take home points on Trastuzumab Deruxtecan ENHERTU®. 

2023-2024 SGO Chemotherapy and Targeted Therapies Subcommittee Member and Moderator:
Tracilyn Hall, MD

Speakers:
Jennifer MacDonald, PharmD, BCOP
Kathleen Moore, MD
Bernard Tawfik, MD 

In honor of Endometrial Cancer Awareness Month, we encourage you to read the latest HER2 Molecular Card and Trastuzumab Deruxtecan ENHERTU® Chemotherapy Card available now on SGO ConnectEd.

HER2 Molecular Card: https://connected.sgo.org/content/molecular-target-human-epidermal-growth-factor-receptor-2-her2

Trastuzumab Deruxtecan ENHERTU® Chemotherapy Card: https://connected.sgo.org/content/chemotherapy-targeted-therapies-flash-cards

In this podcast, we will focus on same day discharge as part of Enhanced Recovery after Surgery (ERAS).

Over the past two decades, and especially after the publication of the GOG LAP2 trial, minimally invasive surgery has been widely adopted in gynecologic oncology, as it is associated with lower rates of complications, and improved postoperative recovery and return to normal activity. 

Postoperative hospitalization is typically shorter after minimally invasive (MIS) hysterectomy, and many patients may even be candidates for discharge on the day of surgery, so-called same-day discharge (SDD).

2023-2024 SGO ERAS Subcommittee Members and Speakers:
Lee-may Chen, MD; Subcommittee Lead and Moderator
Nawar Latif, MD, MPH, MSCE
Clarissa Polen-De, MD
Michael Shu, MD
Collin Sitler, DO
Brenna Swift, MD, MASc, MSc, FRCSC
Diogo Torres, MD

This episode is part 3 of the Immunotherapy podcast series, which continues discussion of common controversies affecting the use of immune checkpoint inhibitors (ICIs) in the clinic, such as optimal dosing strategies, influence of toxicity on response and survival, and sequencing.

Moderator:
Karin K. Shih, MD
Gynecologic Oncologist & Assistant Professor - Zucker School of Medicine at Hofstra/Northwell

Speakers:
Erin Zacholski, PharmD, BCOP
Assistant Professor - VCU School of Pharmacy
Clinical Pharmacy Specialist, Gynecologic Oncology -  VCU Health Massey Cancer Center

Sarah Hayward, PharmD, BCOP
Clinical Pharmacy Specialist, Gynecologic Oncology - OU Health Stephenson Cancer Center

This episode is part 2 of the Immunotherapy Series, which reviews common controversies affecting daily use of immune checkpoint inhibitors (ICIs) in the clinic, such as treatment options for immune related adverse effects beyond corticosteroids, re-challenging after toxicity, use of ICIs in patients with auto-immune conditions, and drug interactions.

Moderator:
Karin K. Shih, MD
Gynecologic Oncologist & Assistant Professor - Zucker School of Medicine at Hofstra/Northwell

Speakers:
Erin Zacholski, PharmD, BCOP
Assistant Professor - VCU School of Pharmacy
Clinical Pharmacy Specialist, Gynecologic Oncology -  VCU Health Massey Cancer Center

Sarah Hayward, PharmD, BCOP
Clinical Pharmacy Specialist, Gynecologic Oncology - OU Health Stephenson Cancer Center